A Spain-based KOL discusses diagnosis and classification of Acute Lymphoblastic Leukemia (ALL), including cytology, flow cytometry, cytogenetics, molecular profiling, and epidemiology distinctions between pediatric and adult. The conversation addresses treatment pathways across disease stages, spanning induction, consolidation, maintenance, relapse/refractory management, and the roles of chemotherapy, TKIs for Ph+ ALL, stem cell transplantation, and central nervous system prophylaxis. The KOL also discusses current and emerging therapeutic modalities, including immunotherapies (blinatumomab, inotuzumab), CAR-T cell therapies, novel targets (e.g., CD7, CD19, CD22, CD123), clinical development directions, and access and reimbursement considerations in Spain.

This interview was conducted on August 08, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.